Literature DB >> 27235214

Development of a Web-Based Decision Support Tool to Operationalize and Optimize Management of Hyperbilirubinemia in Preterm Infants.

Jonathan P Palma1, Yassar H Arain2.   

Abstract

Premie BiliRecs is a novel electronic clinical decision support tool for the management of hyperbilirubinemia in moderately preterm infants less than 35 weeks gestational age. It serves to operationalize and automate current expert consensus-based guidelines, and to aid in the generation of new practice-based evidence to inform future guidelines.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BiliTool; Clinical decision support (CDS); Electronic medical record (EMR); Neonatal preterm hyperbilirubinemia; Practice-based evidence; Premie BiliRecs (PBR)

Mesh：

Year:  2016        PMID： 27235214     DOI： 10.1016/j.clp.2016.01.009

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN： 0095-5108            Impact factor:   3.430


  3 in total

1.  Evaluation of a mobile application tool (BiliNorm) to improve care for newborns with hyperbilirubinemia in Indonesia.

Authors:  Mahendra T A Sampurna; Kinanti A Ratnasari; Zahra S Irawan; Risa Etika; Martono T Utomo; Brigitta I R V Corebima; Pieter J J Sauer; Arend F Bos; Christian V Hulzebos; Peter H Dijk
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

2.  Development and implementation of a mobile device-based pediatric electronic decision support tool as part of a national practice standardization project.

Authors:  Russell J McCulloh; Sarah D Fouquet; Joshua Herigon; Eric A Biondi; Brandan Kennedy; Ellen Kerns; Adrienne DePorre; Jessica L Markham; Y Raymond Chan; Krista Nelson; Jason G Newland
Journal:  J Am Med Inform Assoc       Date:  2018-09-01       Impact factor: 4.497

3.  Model-Informed Precision Dosing of Vancomycin in Hospitalized Children: Implementation and Adoption at an Academic Children's Hospital.

Authors:  Adam Frymoyer; Hayden T Schwenk; Yvonne Zorn; Laura Bio; Jeffrey D Moss; Bhavin Chasmawala; Joshua Faulkenberry; Srijib Goswami; Ron J Keizer; Shabnam Ghaskari
Journal:  Front Pharmacol       Date:  2020-04-29       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.